Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 157 for:    Idiopathic Dilated Cardiomyopathy

Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (LENA-WP08)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02652728
Recruitment Status : Unknown
Verified January 2016 by Ethicare GmbH.
Recruitment status was:  Not yet recruiting
First Posted : January 12, 2016
Last Update Posted : January 12, 2016
Sponsor:
Information provided by (Responsible Party):
Ethicare GmbH

Brief Summary:
Paediatric clinical trial in 50 children, from 1 month to less than 12 years of age, suffering from heart failure due to dilated cardiomyopathy, to obtain paediatric pharmacokinetic and pharmacodynamic data of enalapril and its active metabolite enalaprilat while treated for 8 weeks with enalapril in form of Orodispersible Minitablets (ODMTs), to describe the dose exposure in this patient population.

Condition or disease Intervention/treatment Phase
Heart Failure Dilated Cardiomyopathy Drug: Enalapril Orodispersible Minitablet Phase 2 Phase 3

Detailed Description:

This clinical trial is one of three clinical trials of the European-Commission (FP7)-funded "LENA" (Labeling of Enalapril from Neonates up to Adolescents) project: 50 children with heart failure due to dilated cardiomyopathy (LENA-Work Package (WP) 08 Trial) and 50 children with heart failure due to congenital heart disease (LENA-WP09 Trial) get treated with an optimal dose of enalapril ODMTs for up to 8 weeks after thorough, individualised titration and get invited to join the 10 months Safety Follow-up Study (LENA-WP10 Trial).

In this WP08 Trial children between 1 month and less than 12 years, naive to enalapril treatment or switched from an Angiotensin-Converting Enzyme (ACE)-Inhibitor pre-treatment, receive an Initial Dose to investigate the reaction over 8 hours before a decision on the first dose is made. Always up to 7 days later a next higher dose is given at the hospital, the patient is supervised for 4 and then always 2 hours before a decision on the prescribed dose for the next dosing period is made. In this study protocol a target dose similar to the adult target dose (20 mg of Enalapril in a 70 year old adult result in 0.282 mg/kg/day enalapril) is defined. Enalapril ODMTs of 0.25 mg and 1 mg are available to allow for an individual dose titration scheme.

Weight-dependently, pharmacokinetic (PK) and pharmacodynamic (PD) data are collected once in a full PK/PD day over 12, respectively 6 hours, and single PK/PD samples at each Dose Titration Visit and each bi-weekly Study Control Visit until the Last Visit after 8 weeks of treatment. Blood pressure and renal monitoring is performed at each visit before deciding on the dose level for the next treatment period.

Pharmacogenomics and metabolomics exploratory studies are added as a sub-study to better understand the underlying disease, its progression as well as the impact of ACE-inhibition on cardiac outcome and renal function.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy
Study Start Date : January 2016
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017


Arm Intervention/treatment
Experimental: Drug administration
Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
Drug: Enalapril Orodispersible Minitablet
Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
Other Name: Enalapril ODMT




Primary Outcome Measures :
  1. Area under the Curve (AUC) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure [ Time Frame: 0 hours to 12 hours ]
    Area under the Curve (AUC) of enalapril and enalaprilat are measured at first dose or at any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation

  2. Maximum Concentration (Cmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure [ Time Frame: 0 hours to 12 hours ]
    Maximum Concentration (Cmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation

  3. Time to Maximum Concentration (Tmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure [ Time Frame: 0 hours to 12 hours ]
    Time to Maximum Concentration (Tmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation


Secondary Outcome Measures :
  1. AUC of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets [ Time Frame: 0 hours to 12 hours ]
    AUC of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation

  2. Cmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets [ Time Frame: 0 hours to 12 hours ]
    Cmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation

  3. Tmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets [ Time Frame: 0 hours to 12 hours ]
    Tmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation

  4. Renin [ Time Frame: Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56) ]
    Renin as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation

  5. Angiotensin 1 [ Time Frame: Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit after 8 (day 56) ]
    Angiotensin 1 as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation

  6. Aldosterone [ Time Frame: Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56) ]
    Aldosterone as marker of the renin-angiotensin-aldosterone system at every study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation

  7. Plasma Renin Activity [ Time Frame: Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56) ]
    Plasma Renin Activity as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation

  8. Brain natriuretic peptides (BNP) [ Time Frame: At Screening Visit and then pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42), at Last Visit (day 56) ]
    Brain natriuretic peptides measurement as indicator of disease severity measured at every visit up to the end of treatment at 8 weeks

  9. Acceptability of the ODMTs [ Time Frame: Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56) ]
    Acceptability assessment according to an age-appropriate scale

  10. Palatability of the ODMTs [ Time Frame: Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56) ]
    Palatability assessment according to an age-appropriate scale

  11. Blood pressure [ Time Frame: Pre-dose at each Visit, over 8 hours at Initial Dose Visit, over 4 hours at First Titration Visit (day 3 to 7), over 2 hours after all other Titration Visits, pre-dose at all Study Control Visits (at days 14, 28 and 42), at Last Visit (day 56) ]
    Safety monitoring parameter to decide on next dose prescription level

  12. Serum potassium [ Time Frame: Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56) ]
    Renal monitoring parameter to decide on next dose prescription level

  13. Blood urea nitrogen (BUN) [ Time Frame: Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56) ]
    Renal monitoring parameter to decide on next dose prescription level

  14. Creatinine [ Time Frame: Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56) ]
    Renal monitoring parameter to decide on next dose prescription level

  15. Micro-albuminuria [ Time Frame: Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56) ]
    Renal monitoring parameter to decide on next dose prescription level

  16. Shortening fraction [ Time Frame: Assessment time points: at Screening Visit and at Last Visit (day 56) ]
    Shortening Fraction in echocardiography

  17. Number of patients experiencing rehospitalisation due to heart failure [ Time Frame: During 8 weeks of treatment ]
    Number of patients experiencing rehospitalisation due to heart failure including the need for heart transplantation or the institution of mechanical circulatory support

  18. Death due to worsening of the underlying disease [ Time Frame: During 8 weeks of treatment ]
    Death due to worsening of the underlying disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients presenting with heart failure with signs of left ventricular (LV) systolic dysfunction who are eligible to receive ACE-Inhibitors in addition to standard therapy (e.g., digitalis and diuretics) can be enrolled into this trial. Patients who previously presented with LV systolic dysfunction and who have already been treated with ACE-Inhibitors, and currently still have an indication for the use of an ACE-Inhibitor can be switched to an equivalent starting dose of enalapril ODMT.

Patients fulfilling the following inclusion criteria can be enrolled

  • Age 1 month to less than 12 years.
  • Male and female patients.
  • Diagnosis of dilated cardiomyopathy presenting with LV end-diastolic dimension > P95 and/or LV shortening fraction (SF) < 25%
  • Subjects may be naïve to ACE-Inhibitor.
  • Subjects already on ACE-Inhibitor willing to switch to enalapril Orodispersible Minitablets.
  • Written informed consent from parent(s)/legal representative and assent from the patient according to national legislation and as far as achievable from the child.

Exclusion Criteria:

Patients fulfilling any of the following exclusion criteria cannot be enrolled into this trial:

  • Severe heart failure and/or end stage heart failure precluding introduction or continuation of ACE-Inhibitor.
  • Too low blood pressure, e.g. ˂P5
  • Restrictive and hypertrophic cardiomyopathies.
  • Obstructive valvular disease (peak echocardiographic gradient more than 30 mm Hg).
  • Uncorrected severe peripheral stenosis of large arteries including severe coarctation of the aorta.
  • Severe renal impairment with serum creatinine >2x Upper Limit of Normal (ULN) (according to the hospital's test methodology).
  • History of angioedema.
  • Hypersensitivity to ACE-Inhibitor.
  • Concomitant medication:

    • Dual ACE-Inhibitor therapy
    • Renin inhibitors
    • Angiotensin II antagonists
    • Non-Steroidal Anti-Inflammatory Drugs (including ibuprofen) except for aspirin and paracetamol
  • Already enrolled in an interventional trial with an investigational drug, unless no interference with the current study can be shown.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652728


Contacts
Layout table for location contacts
Contact: Stephanie Laeer, Prof,MD,PhD +49 211 8110740 Stephanie.Laeer@uni-duesseldorf.de
Contact: Ingrid Klingmann, MD, PhD +32 2 7843692 iklingmann@pharmaplex.be

Locations
Layout table for location information
Austria
Medical University of Vienna Not yet recruiting
Vienna, Austria, 1090
Contact: Christoph Male, Prof,MD,PhD    + 43 1 40400 32320    christoph.male@meduniwien.ac.at   
Contact: Vanessa Swoboda, MD    + 43 1 40400 32320    v.swoboda@live.at   
Principal Investigator: Christoph Male, Prof,MD,PhD         
Sub-Investigator: Vanessa Swoboda, MD         
Hungary
Hungarian Paediatric Heart Centre, Göttsegen Gyorgy Hungarian Institute of Cardiology Not yet recruiting
Budapest, Hungary, 1095
Contact: András Szatmári, Prof,MD,PhD    +36 1 215 1220    szatmari@kardio.hu   
Contact: Laszlo Ablonczy, MD    +36 1 215 1220    ablonczyl@gmail.com   
Principal Investigator: András Szatmári, Prof,MD,PhD         
Sub-Investigator: Laszlo Ablonczy, MD         
Netherlands
Sophia Children's Hospital, Erasmus MC Not yet recruiting
Rotterdam, Netherlands, 3015 CN
Contact: Michiel Dalinghaus, MD,PhD    +3110-7040704    'Michiel Dalinghaus' <m.dalinghaus@erasmusmc.nl>   
Contact: Tjitske van der Zanden    +3110-7040704    t.vanderzanden@erasmusmc.nl   
Principal Investigator: Michiel Dalinghaus, MD,PhD         
Sub-Investigator: Marijke Van der Meulen, MD,PjD         
Wilhelmina Children's Hospital, University Medical Center Utrecht Not yet recruiting
Utrecht, Netherlands, 3584 CX
Contact: J.M.P. J. Breur, MD,PhD    + 31 8875 540 02    h.breur@umcutrecht.nl   
Principal Investigator: J.M.P. J. Breur, MD,PhD         
Serbia
Univerzitetska Dečja Klinika Not yet recruiting
Belgrade, Serbia, 11129
Contact: Milica Bajcetic, Prof,MD,PhD    + 38 1112060716    milica.bajcetic@udk.bg.ac.rs   
Contact: Ida Jovanovic, Prof,MD,PhD    + 38 1112060716    idaj@rcub.bg.ac.rs   
Principal Investigator: Ida Jovanovic, Prof,MD,PhD         
United Kingdom
Great Ormond Street Hospital for Children NHS Trust Not yet recruiting
London, United Kingdom, WC1N 3JH
Contact: Michael Burch, Prof,MD,PhD    +44 020 7405 9200    michael.burch@gosh.nhs.uk   
Principal Investigator: Michael Burch, Prof,MD,PhD         
Sponsors and Collaborators
Ethicare GmbH
Investigators
Layout table for investigator information
Study Chair: Michiel Dalinghaus, MD, PhD Sophia Children's Hospital Erasmus MC Rotterdam
Principal Investigator: J.M.P. J. Breur, MD, PhD Wilhelmina Children's Hosptial University Medical Center Utrecht
Principal Investigator: Ida Jovanovic, Prof,MD,PhD Univerzitetska Decja Klinika Belgrade
Principal Investigator: Christoph Male, Prof, MD,PhD Medical University of Vienna
Principal Investigator: Michael Burch, Prof,MD,PhD Great Ormond Street Hospital for Children London
Principal Investigator: András Szatmári, Prof,MD,PhD Hungarian Paediatric Heart Institute, Göttsegen Gyorgy Hungarian Institute of Cardiology Budapest

Additional Information:
Layout table for additonal information
Responsible Party: Ethicare GmbH
ClinicalTrials.gov Identifier: NCT02652728     History of Changes
Other Study ID Numbers: 2015-602295-01
2015-002335-17 ( EudraCT Number )
First Posted: January 12, 2016    Key Record Dates
Last Update Posted: January 12, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Serious Adverse Event information
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Failure
Heart Diseases
Cardiovascular Diseases
Cardiomegaly
Enalapril
Enalaprilat
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents